Celadon Partners
VC Fund
Hong Kong, Hong Kong
Celadon Partners is a private equity manager with a focus on transformative innovations.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Celadon Partners invests in
Stages Celadon Partners invests in
Countries Celadon Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Biopharma 1 (25%)
- Coworking 1 (25%)
- Incubators 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Funding Round 1 (25%)
- Post-IPO Equity 1 (25%)
Country
- Singapore 2 (50%)
- Japan 1 (25%)
- United States 1 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Donald Tang
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer . | $8.5M / Seed / Mar 18, 2025 | |
|
|
Senti Biosciences is a developer of a programmable biology platform for cancer therapies. Its therapeutics specialize in cell engineering and biological programming to build the future of gene and cell-based therapies that enable physicians to give patients life-saving treatments at an affordable cost. | $47.6M / Post-IPO Equity / Dec 02, 2024 | |
|
|
NSG BioLabs is a co-working laboratory made specifically to develop revolutionary biotechnology ventures. The company has a global infrastructure that supports new and growing ventures. With large laboratory benches, several tissue culture suites, a list of shared core equipment, and a group of selected tenants and partners in its sites. It is acomplete global life sciences incubation ecosystem.NSG BioLabs was founded on 2019 and is headquartered in Singapore. | $14.5M / Venture - Series Unknown / May 07, 2024 | |
|
|
GDMC is a pharmaceutical company that engages in manufacturing and designing genetic medicines. | $21M / Series A / Jan 24, 2024 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Celadon Partners invest in?
Celadon Partners invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Celadon Partners?
Public channels for Celadon Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Celadon Partners?
The team at Celadon Partners includes Donald Tang (Founder and Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!